Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PUR001 in advanced solid tumors
NCT05234853Phase 1Unknown
- Sponsor
- Purinomia Biotech
- Start
- Apr 2022
- Primary completion
- Dec 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PUR001 in solid tumor (advanced stage), sponsored by Purinomia Biotech. Primary endpoints: Dose Limiting Toxicity and Maximum Tolerated Dose. Status: unknown.
02
Drugs
PUR001
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05234853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05234853.